Amphotericin B with a liposome bilayer coating (LAmB) has been created to mitigate the dose restriction of traditional amphotericin B deoxycholate (DAmB) while maintaining antifungal activity. Given that Cryptococcosis Treatment are naturally resistant to echinocandins and deploy a variety of responses that give them resistance to azoles there are few effective treatments for invasive cryptococcal infection. A phase II experiment showed that a single high dosage of LAmB is as effective as a seven-day course of DAmB10, demonstrating the significant potential of these lipid formulations. 

The pipeline for developing Cryptococcosis Treatment has to be strengthened more than ever given the ongoing risk that Cryptococcus infections offer to public health. Fortunately, there is a lot of hope for the future thanks to increased interest among scientists in researching and developing new antifungal tactics, such as targeting crucial genes or cellular functions, hindering factors that contribute to virulence, inhibiting stress-response signalling, using compound combinations, and creating immunomodulatory therapies.